BRCA2 and neoplasm: Impaired HR through mutations in BRCA1, BRCA2, PALB2, or potentially other mechanisms, can increase the rate of point mutations and random insertions and deletions, promoting tumor neoantigen formation and presentation, and cytotoxic T-cell infiltration [48].